Bill Detail
S. 1095
Congress: 119
Title
Stop STALLING Act
Summary
Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act or the Stop STALLING Act This bill makes it an unfair method of competition to submit an objectively baseless petition to the Food and Drug Administration (FDA) in an attempt to interfere with a competitor's application for market approval of a drug. The bill authorizes the Federal Trade Commission to sue an individual or entity that submits such a petition to the FDA. A party found liable in such a lawsuit is subject to civil penalties, such as a fine of up to $50,000 for each day that the FDA spent reviewing the baseless petition.
Sponsor
Sen. Amy Klobuchar [D-MN]
Status
Placed on Senate Legislative Calendar under General Orders. Calendar No. 45.
Status as of Jul 31, 6:26 AM · synced 13d ago
Introduced
2025-03-24
Data source mode: congress-gov
Bill Engagement
Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act or the Stop STALLING Act This bill makes it an unfair method of competition to submit…
Lobbyists on the case
- Pharmaceutical Research and Manufacturers of America5 filings · 19 lobs
Prepared intelligence brief
Put this record in the joined picture.
Unlock every organization and lobbyist filing on this bill, the complete event and issue map, private team positions, and recurring movement alerts across the portfolio.